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Abstract
Background. The most prevalent topical treatment for partial thickness burns is silver sulfadiazine 1% (SSD). 
Recent studies have shown that the healing of partial thickness burns is delayed with the use of SSD. One of the 
potential burn dressings is sucralfate.
Objectives. With this study the authors have aimed to analyze comparatively the effects of sucralfate and SSD on 
second degree burn wounds in rats.
Material and Methods. Forty-eight male rats were divided into three equal groups. A burn model was constituted 
on the back of all rats. The burned areas in the first, second and third groups were covered daily with sucralfate, 
SSD and cold cream (control), respectively. At the end of the 7th, 14th, 21st and 28th day, the rats were anesthetized 
and the burned skin tissue samples were collected for histopathological examination.
Results. At the end of the study, the epidermis and horny layer was completely formed in the SSD and sucralfate 
group; however the appendix of skin was just formed in the sucralfate group. Also the percentage of wound healing 
was calculated at 76%, 91% and 100% respectively in the control, silver sulfadiazine and sucralfate groups.
Conclusions. Sucralfate is known to have multiple beneficial effects on wound healing. Using topical sucralfate 
accelerates the burn wound healing process in comparison with both the control and SSD groups and can be used 
as an adjunctive or alternative agent in the future (Adv Clin Exp Med 2013, 22, 4, 481–487).
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Streszczenie
Wprowadzenie. Najbardziej rozpowszechnionym sposobem miejscowego leczenia oparzeń II stopnia jest sól sre-
browa sulfadiazyny 1% (SSD). Ostatnie badania wykazały, że leczenie oparzeń II stopnia jest opóźnione z wykorzy-
staniem SSD. Jednym z możliwych opatrunków oparzeniowych jest sukralfat.
Cel pracy. Analiza porównawcza wpływu sukralfatu i SSD na oparzenia drugiego stopnia u szczurów.
Materiał i metody. Czterdzieści osiem samców szczurów podzielono na trzy równe grupy. Model oparzenia utwo-
rzono na grzbiecie wszystkich szczurów. Spalone obszary w grupach pierwszej, drugiej i trzeciej codziennie pokry-
wano odpowiednio sukralfatem, SSD i zimną śmietaną (grupa kontrolna). Na koniec dnia 7, 14, 21 i 28 szczury 
usypiano i spalone próbki tkanki skóry zebrano do badań histopatologicznych.
Wyniki. Na koniec badania naskórek i warstwa rogowa skóry były całkowicie uformowane w grupie SSD i sukral-
fatu, jednak skóra właściwa została wytworzona w grupie z sukralfatem. Skuteczność gojenia ran obliczono na 76%, 
91% i 100% w grupie kontrolnej, z solą srebrową sulfadiazyny i z sukralfatem.
Wnioski. Sukralfat wywiera korzystny wpływ na gojenie ran. Przy zastosowaniu miejscowym sukralfat przyspieszał 
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Burns are one of the most widespread injuries 
all over the world. In the United States, more than 
1 million burn victims need medical attention ev-
ery year, but only 45,000 of them require hospital-
ization [1]. A similar situation exists in the United 
Kingdom, where burns comprise 1% of the work-
load in emergency wards as well as 0.014% of hos-
pital admissions [2]. Thus, most burns are not se-
vere and could be managed outside the hospital.
The most prevalent topical treatment for 
partial thickness burns is silver sulfadiazine 1% 
(SSD) [1, 3]. SSD is the topical agent of choice for 
severe burns and is used almost universally to-
day in preference to compounds such as silver ni-
trate and mafenide acetate. SSD cream, in spite of 
being effective, causes some systemic side effects 
consisting of neutropenia, erythema multiforme, 
crystalluria and methemoglobinemia [4–6]. Top-
ical agents which are used only as antimicrobials 
include silver nitrate, sulfamylon and a combina-
tion of a sulfonamide and SSD. Sulfamylon has 
broad spectrum activities, but it is easily absorbed 
systemically and can lead to toxic complications. 
SSD has become the standard topical treatment for 
burn wounds [4]. More recent studies have shown 
that the healing of partial thickness burns is de-
layed with the use of SSD [7, 8], indicating the 
need for a better burn dressing.
One of the potential burn dressings is sucral-
fate. Sucralfate is a basic aluminum complex of 
sucrose sulfate and a cytoprotective agent. The 
sporadic studies and case reports available in the 
literature are all consistent, indicating the favor-
able effect of topical sucralfate in wound repair 
and skin protection. Almost all studies have indi-
cated the safe and effective behavior of this com-
pound [9–17]. Sucralfate has also been shown to 
have antibacterial activity [18, 19] and has been 
successfully studied in decreasing pain and im-
proving healing after hemorrhoidectomy [20], in 
peristomal and perineal dermatoses, in moist des-
quamation during radiotherapy, in erosion and ul-
ceration of the perineal area, in vaginal ulceration, 
in dystrophic epidermolysis bullosa, in second and 
third degree burns, and in a pilot trial with non-
healing, full-thickness venous stasis ulcers refrac-
tory to 8 weeks of conventional therapy [9–17].
With this study the authors aimed to analyze 
comparatively the effects of sucralfate and SSD 
on wound healing in a burn wound that has been 
made in rats.
Material and Methods
Animals
Forty-eight male Wistar rats (200 to 250 g each) 
were obtained from the Razi Institute (Karaj, Iran) 
and housed in groups of three per cage under stan-
dard laboratory conditions. All animals were kept 
at a constant room temperature (21 ± 2ºC) under 
a normal 12-h light/12-h dark cycle with free ac-
cess to food and water. All animal experiments 
were carried out in accordance with the european 
Union’s Council Directive of November 24th, 1986 
(86/609/eeC) to minimize their suffering.
Chemicals
Sucralfate cream (Avene Cicalfate Restorative 
Skin Cream, purchased from Avene Co., France), 
silver sulfadiazine 1% (topical cream, purchased 
from Sobhan Pharmaceutical Co., Tehran, Iran), 
cold cream (Botafarma, 12.5% spermaceti + 12% 
white wax + 56% liquid paraffin + 0.5% borate of 
soda + 19% distilled water) [21], ketamine (Rotex-
medica, GmbH, Germany), and xylazine (loughrea 
Co., Galway, Ireland) were used in this study.
Method
All animals were administered general anesthe-
sia through peritoneal injection of xylazine (5 mg/kg) 
and ketamine (40 mg/kg) and the back hair of them 
was shaved. Then a round iron plate (heated to 80°C) 
was placed on each animal’s skin for 1 second in order 
to create a 1.75 cm2 second-degree burn injury [22]. 
Then the animals received an intraperitoneal injec-
tion of saline (0.1 l/kg) and were placed in individu-
al cages for recovery. To confirm the degree of burns, 
histopathological samples were taken randomly from 
eight rats. Then all animals were randomly divided 
into three groups (n = 16 in each group). The first 
group was treated with sucralfate cream, the second 
group was treated with the silver sulfadiazine 1% and 
the third group was treated with cold cream.
By considering the day that the authors caused 
burn in rats as zero, the punch biopsies with dispos-
able punch were taken of the large diameter wound 
burn and surrounding skin of 12 animals (n = 4 
in each group) at the end of the 7th, 14th, 21st and 
28th day (needle size = 8 mm). Skin sections were 
fixed in 10% formaldehyde, dehydrated in ethanol 
(50% to 100%), cleared in xylene and embedded in 
proces gojenia ran po oparzeniu w porównaniu z grupą kontrolną i SSD oraz może być stosowany jako alternatywa 
lub środek wspomagający leczenie w przyszłości (Adv Clin Exp Med 2013, 22, 4, 481–487).
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paraffin. Sections (4 to 5 µm thick) were prepared 
and stained with hematoxylin and eosin (He) dyed 
for histopathological examination and observed 
under a microscope at a high magnification. The 
thickness of granulation tissue at the center of each 
wound was examined and recorded. Also, to deter-
mine the percentage of wound healing, the wound 
surface was measured by tracing the margins of the 
open wound on digital images of the wounds that 
were scanned into the computer. The open wound 
area was then later calculated using Scion Image 
version beta 4.0.2 (Scion, Frederick, Md) on the 
aforementioned days (7th, 14th, 21st and 28th). Af-
ter that, the following formulas were used to deter-
mine the percentage of wound and healing:
Area of wound = Open wound area was calcu-
lated using Scion Image (details above)
Percentage of wound = (Area of wound on 
particular day × 100) ÷ the area of wound on the 
first day
Percentage of healing = (100 – percentage of 
wound)
Ethical Approval
The study was approved by the ethics commit-
tee of the Qazvin University of Medical Science 
before its initiation, and the protocols used con-
formed to the ethical guidelines of the 1975 Hel-
sinki Declaration.
Statistical Analysis
The collected data was analyzed using SPSS 
software (Statistical Package for the Social Scienc-
es, version 11.0, SPSS Inc, Chicago, Ill, USA). One-
way ANOVA tests were used, where appropriate, for 
comparing data between all groups. Continuous da-
ta was demonstrated as mean ± standard deviation. 
P – values less than 0.05 were considered significant.
Results
At the End of the First Week
In all groups, no epidermis existed in the burn 
site and fibrino-leukocytic exudate was seen with 
edema and transudates in the wound and surround-
ing tissue. A necrotic layer with predominant in-
flammatory PMN cells and granulation tissue with 
angiogenesis were seen in all groups (Fig.  1).
At the End of the Second Week
In the sucralfate group, the thickness of the fi-
brino-leukocytic layer was decreased in comparison 
with the control and SSD groups, although granu-
lation tissue had increased. Fibroblast density was 
increased in the dermal layer in all groups, in addi-
tion to this increase; angiogenesis was also greatest 
in the sucralfate group. The percentage of inflam-
matory PMN cells was reduced while the number 
of mononuclear inflammatory cells had started to 
increase (Fig. 2).
Fig. 1. The first week in the third group (high mag-
nification ×400): exudative and necrotic layer at first 
week. The predominant inflammatory cells are PMN
Ryc. 1. Stan w pierwszym tygodniu w trzeciej grupie. 
(duże powiększenie 400×): wysiękowe i martwicze 
warstwy w pierwszym tygodniu. Dominujące komórki 
zapalne to granulocyty obojętnochłonne
Fig. 2. The second week in the first group (high magni-
fication ×400): The granulation tissue is present. There 
is more vascular proliferation than in the first week. 
There is a decrease in the percentage of PMN inflam-
matory cells and the mononuclear inflammatory cells 
begin to increase in numbers
Ryc. 2. Drugi tydzień w pierwszej grupie (duże 
powiększenie 400×): są obecne wysiękowe, martwicze 
i zianinowe warstwy. Istnieje więcej proliferacji niż 
w pierwszym tygodniu. Zmniejszył się odsetek komó-
rek zapalnych granulocytów obojętnochłonnych i jest 
coraz więcej jednojądrzastych komórek zapalnych
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At the End of the Third Week
In the control group, the cells in the wound 
bed were more organized. The epidermis layer was 
not formed and fibroblast density had increased 
in this layer. In the silver sulfadiazine group, de-
spite forming an epidermis layer, the horny layer 
hadn’t formed and in the sucralfate group, the epi-
dermis layer as well as a thin horny layer were seen. 
like new parallel blood vessels in the silver sulfa-
diazine group were also seen on the wound surface 
in this group. The granulation tissue was more or-
ganized than other groups. In this week, the per-
centage of inflammatory PMN cells was reduced 
and density of fibroblast and macrophage was in-
creased (Fig. 3).
At the End of the Forth Week
In the control group, the epidermis layer had 
formed in spite of the fact that some areas showed 
lack of epidermis in the center of the wound. 
The horny layer was created in the middle of the 
wound, otherwise there wasn’t any in the center of 
the wound. In this week in the silver sulfadiazine 
group, the epidermis and horny layer was com-
pletely formed, however the appendix of skin was 
not formed.
In the sucralfate group, the epidermis and 
horny layer was completely formed at the end of 
the 4th week. There was fibrous tissue in the central 
part of the lesion. The inflammatory cells’ content 
was reduced and a low number of mononuclear in-
flammatory cells was seen (Fig. 4).
At the end of the fourth week, the percentage 
of wound healing was calculated at 76%, 91% and 
100%, respectively, in the control, silver sulfadia-
zine and sucralfate groups. This result was signifi-
cantly different between all groups (p < 0.05). The 
percentage of wound healing in this study is sum-
marized in Table 1 and Fig. 5. Also, present re-
sults in this study have shown that the thickness 
of granulation tissue was significantly different 
between each group (p < 0.05). The mean values 
of thickness of granulation tissue in the center of 
the wounds for sucralfate cream, SSD and control 
groups are shown in Table 2.
Fig. 3. The third week in the first group (High mag-
nification ×400): There is decrease in the number of 
inflammatory cells, particularly PMNs, and an increase 
in the number of macrophages and fibroblasts. A fine 
deposit of collagen matrix is also present
Ryc. 3. Stan w trzecim tygodniu w pierwszej grupie 
(duże powiększenie 400×). Zmniejszyła się liczba 
komórek zapalnych, w szczególności granulocytów 
obojętnochłonnych i zwiększyła się liczba makrofagów 
i fibroblastów. Cienka warstwa macierzy kolagenowej 
jest również obecna
Fig. 4. The fourth week in the first group (high mag-
nification ×400): The inflammatory cells are scat-
tered and are mostly mononuclear. Vascularity is also 
decreased. There is a higher number of fibroblasts than 
normal and more deposits of collagenous matrix (scar 
tissue formation)
Ryc. 4. Stan w czwartym tygodniu w pierwszej grupie 
(duże powiększenie 400×): komórki zapalne są roz-
proszone, w większości jednojądrzaste. Unaczynienie 
również zmniejszyło się. Istnieje większa liczba fibro-
blastów niż normalnie i więcej warstw macierzy kola-
genowej (powstawanie blizn)
Fig. 5. Wound area (mm2) over 4-week treatment
Ryc. 5. Obszar rany (mm2) podczas 4-tygodniowego 
leczenia
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Discussion
Wound repair depends on neoangiogenesis, 
the activation of local immune response, and in 
the presence of growth factors including epider-
mal growth factor (eGF), transforming growth 
factor b (TGF-b), and basic fibroblast growth fac-
tor (bFGF) [23–27].
Sucralfate is known to have multiple benefi-
cial effects on wound healing. This drug induces 
the proliferation of dermal fibroblasts and kera-
tinocytes in vitro, and inhibits the release of in-
terleukin-2 and interferon-γ from damaged skin 
cells [28]. The physical barrier feature of sucral-
fate is to diminish inflammatory reaction and im-
prove mucosal healing [17, 29–31]. limiting the 
inflammation might decrease fibrosis and stric-
ture formation and eGF expression as well as the 
expression of other factors involved in tissue re-
pair processes [32]. Stimulating effects on vascular 
factors, such as angiogenesis, which play impor-
tant roles in tissue repair, have been demonstrat-
ed by sucralfate [33, 34]. Sucralfate does not have 
any adverse effects [35] thus it is widely employed 
in clinical practice to prevent or treat recurrent 
aphthous stomatitis and several gastrointestinal 
diseases [36, 37].
Unfortunately not many in vivo or in vitro his-
topathological studies about this drug have been 
carried out in the world. Because of that, the main 
objective of this study was to determine the effec-
tiveness of the local treatment of burn wounds 
with sucralfate and compare it to SSD.
According to the results that were obtained in 
this study, using topical sucralfate accelerates the 
burn wound healing process in comparison to both 
the control and SSD groups, so that at the end of 
the fourth week, thickness of granulation tissue was 
significantly higher in the sucralfate group. Also, 
the percentage of wound healing was calculated at 
76%, 91% and 100%, respectively, in the control, sil-
ver sulfadiazine and sucralfate groups. These results 
confirm another study about the role of granulation 
tissue in wound healing [38] and demonstrate the 
power of sucralfate in neoangiogenesis, prolifera-
tion of dermal fibroblasts, eGF expression and the 
expression of other factors involved in tissue repair 
processes. This is in concurrence with other studies, 
which have shown that sucralfate stimulates epithe-
lial cell proliferation by causing accumulation of 
epidermal growth factor in the ulcerated areas [39, 
40]. Burch et al. [28] showed, in animal studies, that 
sucralfate cream accelerates cell proliferation in the 
superficial skin layer, leading to a clear thickening 
of the epidermis the same as in dermis experimen-
tal studies by Szabo et al. [34] that have shown that 
sucralfate stimulates angiogenesis, which increas-
es granulation tissue. Moreover, sucralfate induced 
PGe2 synthesis and Il-6 release from cultured skin 
cells in the study by Burch et al. [28], which was re-
sponsible for the healing process.
Limitations
Unfortunately present study has several limi-
tations. The small sample size may have led to an 
important error. Furthermore, the current study 
was limited to 28 days only, during which time, all 
the wounds did not heal completely. On the other 
Table 2. Thickness (mm) of granulation tissue in the center of the wound
Tabela 2. Grubość (mm) tkanki ziarninowej na środku rany
1st week (Tydzień 1) 2nd week (Tydzień 2) 3rd week (Tydzień 3) 4th week (Tydzień 4)
Sucralfate group 0.985 ± 0.01 1.856 ± 0.03 2.580 ± 0.01 3.200 ± 0.02
SSD group 0.736 ± 0.02 1.214 ± 0.03 2.010 ± 0.03 2.765 ± 0.01
Control group 0.380 ± 0.05 0.896 ± 0.01 1.520 ± 0.03 2.000 ± 0.01
P-Value P < 0.05* P < 0.05* P < 0.05* P < 0.05*
Table 1. The percentages of wound healing
Tabela 1. Odsetek wyleczonych ran
1st week (Tydzień 1) 2nd week (Tydzień 2) 3rd week (Tydzień 3) 4th week (Tydzień 4)
Sucralfate group 6 26 80 100
SSD group 5 24 72 91
Control group 3 14 35 76
P-Value P > 0.05 P < 0.05* P < 0.05* P < 0.05*
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hand, the burned areas in this study were covered 
daily, while 2 or 3 dressing per day probably would 
have a better outcome in wound healing. Finally, 
this study is limited to rats with second degree 
burns and may not generalize to humans.
The authors concluded that in a burn wound 
model in rats, sucralfate was found to expedite the 
healing process both histopathologically and statis-
tically as compared to SSD and the control group. 
Sucralfate powder is a very cheap, safe and well-
tolerated drug in addition having a lack of side ef-
fects. In the usage of oral medication, aluminum is 
poorly absorbed and this drug is excreted through 
the kidneys [41] and in patients with renal disease 
should be prescribed with caution. However topi-
cal medication, due to its low concentration and 
lack of absorption through the skin, doesn’t have 
any such complications [42]. SSD ointment in pa-
tients with allergy to sulfonamides can have se-
vere complications. Another advantage of these 
drugs is the ability to be used in children and in all 
parts of the skin. Through its antimicrobial, anti-
oxidant, anti-inflammatory and immunomodula-
tory effects, sucralfate can be used as an adjunctive 
or alternative agent in wound healing therapies in 
the future. However, further studies are certainly 
needed to shed more light on the healing mecha-
nism of sucralfate.
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